U.S. FDA approves GSK’s Votrient (pazopanib) for mrcc

Votrient, a once-daily, oral medication, is an angiogenesis inhibitor which may help prevent the growth of new blood vessels, thereby blocking the growthof kidney cancer tumors that need blood vessels to survive.

The new drug submission (NDS) for Pazopanib is currently under review by Health Canada.

See Press Release of FDA approval for more information.

FDA Approves GlaxoSmithKline’s VOTRIENT

Kidney Cancer Canada